Equity Overview
Price & Market Data
Price: $87.29
Daily Change: +$1.09 / 1.25%
Daily Range: $87.29 - $87.29
Market Cap: $4,563,607,552
Daily Volume: 169
Performance Metrics
1 Week: 8.50%
1 Month: 32.21%
3 Months: 133.7%
6 Months: 146.7%
1 Year: 452.2%
YTD: 109.2%
Company Details
Employees: 92
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.